The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ARRB1 mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ARRB1 protein]
Mesalamine inhibits the reaction [Acetic Acid results in decreased expression of BCL2 mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of BCL2 protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BCL2 mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BCL2 protein]
Mesalamine inhibits the reaction [Acetic Acid results in increased expression of CASP3 mRNA]; Mesalamine inhibits the reaction [Thioacetamide affects the expression of CASP3 protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of and results in increased cleavage of CASP3 protein]
[Mesalamine co-treated with Glucocorticoids] results in decreased expression of CCL20 mRNA; Mesalamine results in decreased expression of [IL1B protein results in increased expression of CCL20 protein]; Mesalamine results in decreased expression of [TNF protein results in increased expression of CCL20 protein]
Mesalamine promotes the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of GCLM mRNA]
Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with resveratrol] results in increased expression of HMOX1 mRNA] Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of HMOX1 protein]
[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased activity of NFE2L2 protein; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of GCLC mRNA; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of PPARG protein; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with cyanidin-3-O-beta-glucopyranoside] results in increased expression of PPARG protein]; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Resveratrol] results in increased expression of HMOX1 mRNA]; Mesalamine promotes the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of GCLM mRNA]
Mesalamine inhibits the reaction [Acetic Acid results in decreased expression of IL10 protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of IL10 protein]
[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased activity of NFE2L2 protein; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of GCLC mRNA; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of PPARG protein; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with cyanidin-3-O-beta-glucopyranoside] results in increased expression of PPARG protein]; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Resveratrol] results in increased expression of HMOX1 mRNA]; Mesalamine promotes the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of GCLM mRNA]
Mesalamine results in increased expression of IL1B mRNA Mesalamine results in decreased expression of [IL1B protein results in increased expression of CCL20 protein] [allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]; [allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Acetic Acid results in increased expression of IL1B mRNA]; Mesalamine inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein] Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]
Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein] Mesalamine inhibits the reaction [Acetic Acid results in increased expression of IL6 protein]
Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] Mesalamine inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
Mesalamine inhibits the reaction [Acetic Acid results in increased expression of MTOR mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased phosphorylation of MTOR protein]
[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased activity of NFE2L2 protein Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid affects the expression of NFE2L2 protein]
Mesalamine inhibits the reaction [Acetic Acid results in increased expression of NOS2 mRNA] Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of NOS2 protein]
Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of OPRD1 mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of OPRD1 protein]
[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of PPARG protein; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with cyanidin-3-O-beta-glucopyranoside] results in increased expression of PPARG protein] Mesalamine inhibits the reaction [Dextran Sulfate affects the localization of PPARG protein]
Mesalamine inhibits the reaction [Acetic Acid results in increased expression of RELA protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased phosphorylation of RELA protein] Mesalamine results in increased expression of and affects the localization of RELA protein
SLCO1B3 protein results in increased uptake of Mesalamine Budesonide inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Cyclosporine inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]
[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased activity of NFE2L2 protein; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of GCLC mRNA; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of PPARG protein; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with cyanidin-3-O-beta-glucopyranoside] results in increased expression of PPARG protein]; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Resveratrol] results in increased expression of HMOX1 mRNA]; Mesalamine promotes the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of GCLM mRNA]; Mesalamine promotes the reaction [Endotoxins results in increased expression of TNF protein]; Mesalamine results in decreased expression of [TNF protein results in increased expression of CCL20 protein] [allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Thioacetamide results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]
browse the term
